West Pharmaceutical Services (NYSE:WST) Lifted to “Buy” at StockNews.com

West Pharmaceutical Services (NYSE:WSTGet Rating) was upgraded by StockNews.com from a “hold” rating to a “buy” rating in a research note issued on Monday.

Several other analysts also recently commented on WST. William Blair reiterated an “outperform” rating on shares of West Pharmaceutical Services in a report on Tuesday, February 22nd. Zacks Investment Research downgraded shares of West Pharmaceutical Services from a “buy” rating to a “hold” rating and set a $450.00 price objective for the company. in a report on Saturday, January 8th.

WST opened at $381.22 on Monday. The company has a current ratio of 2.93, a quick ratio of 2.30 and a debt-to-equity ratio of 0.09. The company’s fifty day moving average price is $392.53 and its two-hundred day moving average price is $410.48. West Pharmaceutical Services has a 1-year low of $301.16 and a 1-year high of $475.35. The company has a market cap of $28.32 billion, a price-to-earnings ratio of 43.82, a PEG ratio of 4.27 and a beta of 1.06.

West Pharmaceutical Services (NYSE:WSTGet Rating) last announced its earnings results on Thursday, February 17th. The medical instruments supplier reported $2.04 EPS for the quarter, beating the Thomson Reuters’ consensus estimate of $1.92 by $0.12. The company had revenue of $730.80 million during the quarter, compared to the consensus estimate of $710.20 million. West Pharmaceutical Services had a net margin of 23.37% and a return on equity of 31.20%. The firm’s revenue for the quarter was up 26.0% on a year-over-year basis. During the same quarter in the prior year, the company posted $1.34 earnings per share. As a group, equities analysts forecast that West Pharmaceutical Services will post 9.28 earnings per share for the current fiscal year.

In other West Pharmaceutical Services news, VP Quintin J. Lai sold 8,016 shares of the stock in a transaction dated Monday, March 14th. The shares were sold at an average price of $371.69, for a total transaction of $2,979,467.04. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Company insiders own 0.66% of the company’s stock.

Institutional investors have recently made changes to their positions in the business. Bell Investment Advisors Inc bought a new stake in West Pharmaceutical Services during the third quarter valued at approximately $25,000. Monolith Advisors bought a new stake in West Pharmaceutical Services during the fourth quarter valued at approximately $29,000. American National Bank lifted its position in West Pharmaceutical Services by 55.6% during the first quarter. American National Bank now owns 98 shares of the medical instruments supplier’s stock valued at $40,000 after purchasing an additional 35 shares during the last quarter. Herold Advisors Inc. bought a new stake in West Pharmaceutical Services during the third quarter valued at approximately $42,000. Finally, Northwest Investment Counselors LLC bought a new stake in West Pharmaceutical Services during the fourth quarter valued at approximately $47,000. Institutional investors and hedge funds own 91.24% of the company’s stock.

West Pharmaceutical Services Company Profile (Get Rating)

West Pharmaceutical Services, Inc designs, manufactures, and sells containment and delivery systems for injectable drugs and healthcare products in the Americas, Europe, the Middle East, Africa, and the Asia Pacific. It operates in two segments, Proprietary Products and Contract-Manufactured Products.

Featured Stories

Receive News & Ratings for West Pharmaceutical Services Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for West Pharmaceutical Services and related companies with MarketBeat.com's FREE daily email newsletter.